Alcon: Cataract trials

The registry lists 113 Cataract studies with Alcon as lead sponsor. 4 are open to participants now and 73 have results posted.

Phase 2 2Phase 3 14Phase 4 24No phase 73(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Comparison of Corneal Aberrations in Subjects With Contralateral AcrySof IQ Toric Intraocular Lens (IOL) and AcrySof IQ IOL With Limbal Relaxing Incision (LRI)CompletedNCT01045733Not applicable
• Comparison of Corneal Aberrations and Visual Outcomes in AcrySof IQ Toric Patients Versus Limbal Relaxing Incision (LRI) PatientsWithdrawnNCT00929747Phase 4
• Investigation of Corneal Aberrations and Visual Outcomes in Patients Implanted With an AcrySof Toric Intraocular Lens (IOL)WithdrawnNCT00878839Not applicable
• Effect on Wound Healing of Vigamox Versus CravitCompletedNCT00840580Phase 4
• Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® ToricWithdrawnNCT00761488Phase 4
• Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOLWithdrawnNCT00760058Phase 4
• A Clinical Study of Tobradex AFCompletedNCT00473070Phase 3
• Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and PlaceboCompletedNCT00405730Phase 3
• A Bioequivalence Study of Tobradex AFCompletedNCT00362895Phase 3
• Safety of NGOIS Compared to BSS Plus in Pediatric PatientsCompletedNCT00346528Phase 3
• Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS PlusCompletedNCT00333268Phase 3
• Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract SurgeryCompletedNCT00333255Phase 3
• Nevanac 3-Month Safety Study With QID DosingCompletedNCT00332774Phase 3